Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Explore linked clinical trials.8 results · Page 1 of 1
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3) | Psychosis Associated With Alzheimer's Disease | Recruiting | Phase 3 | 2026-09-29 | NCT05980949 | |
| Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia | Schizophrenia Spectrum and Other Psychotic Disorders, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-28 | NCT07686263 | |
| A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents | Schizophrenia Spectrum and Other Psychotic Disorders, autism, autism spectrum disorder, neurodevelopmental disorder, pervasive developmental disorder, psychiatric disorder, schizophrenia | Recruiting | Phase 3 | 2026-09-22 | NCT07424404 | |
| A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) | Alzheimer disease, Psychotic Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, neurodegenerative disease, psychiatric disorder, tauopathy | Recruiting | Phase 3 | 2026-09-22 | NCT06585787 | |
| Study to Assess Safety and Tolerability of KarXT With Administration of Antiemetics in Healthy Volunteers | Nausea, Pathological Conditions, Signs and Symptoms, Signs and Symptoms, Signs and Symptoms, Digestive, Vomiting | Recruiting | Phase 4 | 2026-09-18 | NCT07681076 | |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2) | Psychosis Associated With Alzheimer's Disease | Recruiting | Phase 3 | 2026-09-04 | NCT06126224 | |
| A Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-1) | Psychosis Associated With Alzheimer's Disease | Recruiting | Phase 3 | 2026-08-17 | NCT05511363 | |
| A Study to Evaluate the Effects of CYP2D6 Phenotypes on the Pharmacokinetics of Xanomeline Following KarXT Administration in Healthy Adult Participants | Healthy Volunteers | Recruiting | Phase 1 | 2026-02-19 | NCT07204418 |